Risk Factors Associated with Hepatitis C Subtypes and the Evolutionary History of Subtype 1a in Mexico
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Population and Design
2.2. RNA Isolation and Reverse Transcription
2.3. HCV Genotyping/Subtyping
2.4. Bayesian Coalescent Analysis of HCV Subtype 1a
2.5. Statistical Analysis
2.6. Ethics
3. Results
3.1. General Characteristics of the Study Population
3.2. Frequency of HCV Subtypes by Risk Factors
3.3. Risk Factors Associated with HCV Subtypes
3.4. HCV Subtype 1a Evolution in Mexico
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- World Health Organization. Hepatitis C; World Health Organization: Geneva, Switzerland, 2024; p. 1. Available online: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (accessed on 3 June 2024).
- International Committee on Taxonomy of Viruses (ICTV). Hepacivirus C Classification. Available online: https://ictv.global/sg_wiki/flaviviridae/hepacivirus (accessed on 3 June 2024).
- Petruzziello, A.; Marigliano, S.; Loquercio, G.; Cozzolino, A.; Cacciapuoti, C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World. J. Gastroenterol. 2016, 22, 7824–7840. [Google Scholar] [CrossRef]
- Lohmann, V.; Roos, A.; Korner, F.; Koch, J.O.; Bartenschlager, R. Biochemical and structural analysis of the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. J. Viral Hepat. 2000, 7, 167–174. [Google Scholar] [CrossRef]
- Argentini, C.; Genovese, D.; Dettori, S.; Rapicetta, M. HCV genetic variability: From quasispecies evolution to genotype classification. Future Microbiol. 2009, 4, 359–373. [Google Scholar] [CrossRef]
- Alter, H.J.; Holland, P.V.; Morrow, A.G.; Purcell, R.H.; Feinstone, S.M.; Moritsugu, Y. Clinical and serological analysis of transfusion-associated hepatitis. Lancet 1975, 2, 838–841. [Google Scholar] [CrossRef]
- Velazquez, O.; Stetler, H.C.; Avila, C.; Ornelas, G.; Alvarez, C.; Hadler, S.C.; Bradley, D.W.; Sepulveda, J. Epidemic transmission of enterically transmitted non-A, non-B hepatitis in Mexico, 1986–1987. JAMA 1990, 263, 3281–3285. [Google Scholar] [CrossRef]
- Alter, H.J.; Houghton, M. Clinical Medical Research Award. Hepatitis C virus and eliminating post-transfusion hepatitis. Nat. Med. 2000, 6, 1082–1086. [Google Scholar] [CrossRef]
- Villarreal Urenda, C.; Cano Domínguez, C.; Zamalloa Torres, V.; Ruiz-Maya Lilia, Olivares-López, F. Hepatitis post transfusión. Estudio prospectivo. Gac. Medica Mex. 1991, 127, 13–136. [Google Scholar]
- Campos-Aguirre, E.; Benitez-Arvizu, G. History of the 60 years of the 21th Century National Medical Center’s Central Blood Bank. Rev. Med. Inst. Mex. Seguro Soc. 2023, 61, S72–S80. [Google Scholar]
- Roger, S.; Ducancelle, A.; Le Guillou-Guillemette, H.; Gaudy, C.; Lunel, F. HCV virology and diagnosis. Clin. Res. Hepatol. Gastroenterol. 2021, 45, 101626. [Google Scholar] [CrossRef]
- Norma Oficial Mexicana NOM. 003/SSA2/1993. Normas y Técnicas para la Disposición de Sangre Humana y sus Componentes con Fines Terapéuticos. Diario Oficial de la Federación del 18 de Julio del 1994. Available online: http://www.salud.gob.mx/unidades/cdi/nom/003ssa23.html (accessed on 22 June 2024).
- Rivas-Estilla, A.M.; Sanchez, L.V.; Matsui, O.; Campollo, O.; Armendariz-Borunda, J.; Segura-Ortega, J.E.; Panduro, A. Identification of Hepatitis C Virus (HCV) Genotypes Patients from West of Mexico. Hepatol. Res. 1998, 12, 121130. [Google Scholar]
- Rivas-Estilla, A.M.; Cordero-Pérez, P.; del Carmen Trujillo-Murillo, K.; Ramos-Jiménez, J.; Chen-López, C.; de Garza-Rodríguez, M.L.; Ramírez-Gutiérrez, Á.; Muñoz-Espinosa, L. Genotyping of Hepatitis C Virus (HCV) in Infected Patients from Northeast Mexico. Ann. Hepatol. 2008, 7, 144–147. [Google Scholar] [CrossRef]
- Chiquete, E.; Sánchez, L.V.; Panduro, A. Routes of infection and clinical outcome of Mexican women reactive to anti-hepatitis C virus antibodies. Hepatol. Res. 2006, 36, 100–106. [Google Scholar] [CrossRef]
- Panduro, A.; Roman, S.; Khan, A.; Tanaka, Y.; Kurbanov, F.; Martinez-Lopez, E.; Campollo, O.; Hernandez-Nazara, Z.; Mizokami, M. Molecular Epidemiology of Hepatitis C Virus Genotypes in West Mexico. Virus Res. 2010, 151, 19–25. [Google Scholar] [CrossRef]
- Muñoz-Espinosa, L.E.; Trujillo-Trujillo, M.E.; Martínez-Macías, R.F.; Panduro, A.; Rivas-Estilla, A.M.; Fierro, N.A.; Silvera-Linares, A.L.; Torres-Valadez, R.; Cordero-Pérez, P.; González-Aldaco, K.; et al. Increase of Drug Use and Genotype 3 in HCV-Infected Patients from Central West and Northeast Mexico. Ann. Hepatol. 2015, 14, 642–651. [Google Scholar] [CrossRef]
- Sedeno-Monge, V.; Laguna-Meraz, S.; Santos-Lopez, G.; Panduro, A.; Sosa-Jurado, F.; Jose-Abrego, A.; Melendez-Mena, D.; Munoz-Ramirez, M.A.; Cosme-Chavez, M.; Roman, S. A comprehensive update of the status of hepatitis C virus (HCV) infection in Mexico-A systematic review and meta-analysis (2008–2019). Ann. Hepatol. 2021, 20, 100292. [Google Scholar] [CrossRef]
- Villanueva, M.M. Experiencia de la prueba de NAT en el banco de sangre del Instituto Nacional de Cancerología, México, D.F. Rev. Mex. Med. Transfus. 2009, 2, 69–71. [Google Scholar]
- Sosa-Jurado, F.; Palencia-Lara, R.; Xicoténcatl-Grijalva, C.; Bernal-Soto, M.; Montiel-Jarquin, Á.; Ibarra-Pichardo, Y.; Rosas-Murrieta, N.H.; Lira, R.; Cortes-Hernandez, P.; Santos-López, G. Donated Blood Screening for HIV, HCV and HBV by ID-NAT and the Residual Risk of Iatrogenic Transmission in a Tertiary Care Hospital Blood Bank in Puebla, Mexico. Viruses 2023, 15, 1331. [Google Scholar] [CrossRef]
- Panduro, A.; Roman, S. Need of righteous attitudes towards eradication of hepatitis C virus infection in Latin America. World. J. Gastroenterol. 2016, 22, 5137–5142. [Google Scholar] [CrossRef]
- Prince, A.M. Non-A, non-B hepatitis viruses. Annu. Rev. Microbiol 1983, 37, 217–232. [Google Scholar] [CrossRef]
- Jose-Abrego, A.; Trujillo-Trujillo, M.E.; Laguna-Meraz, S.; Roman, S.; Panduro, A. Epidemiology of Hepatitis C Virus in HIV Patients from West Mexico: Implications for Controlling and Preventing Viral Hepatitis. Pathogens 2024, 13, 360. [Google Scholar] [CrossRef]
- Yee, L.J.; Weiss, H.L.; Langner, R.G.; Herrera, J.; Kaslow, R.A.; van Leeuwen, D.J. Risk factors for acquisition of hepatitis C virus infection: A case series and potential implications for disease surveillance. BMC Infect. Dis. 2001, 1, 8. [Google Scholar] [CrossRef]
- Volkow, P.; Ponce de Leon, S.; Calva, J.; Ruiz-Palacios, G.; Mohar, A. Transfusion associated AIDS in Mexico. Clinical spectrum, conditional latency distribution, and survival. Rev. Investig. Clin. 1993, 45, 133–138. [Google Scholar]
- Kenny-Walsh, E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N. Engl. J. Med. 1999, 340, 1228–1233. [Google Scholar] [CrossRef] [PubMed]
- Schiff, R.I. Transmission of viral infections through intravenous immune globulin. N. Engl. J. Med. 1994, 331, 1649–1650. [Google Scholar] [CrossRef] [PubMed]
- Chiquete, E.; Panduro, A. Low prevalence of anti-hepatitis C virus antibodies in Mexico: A systematic review. Intervirology. 2007, 50, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Fernández Velázquez Juan Antonio, S.T.B. A History of Opium Commodity Chains in Mexico, 1900–1950. J. Illicit. Econ. Dev. 2022, 4, 113–127. [Google Scholar] [CrossRef]
- Coppinger, S.E. High in the City: A History of Drug Use in Mexico City, 1960–1980. Ph.D. Thesis, Department of History, Columbia University, New York, NY, USA, 22 September 2020. [Google Scholar] [CrossRef]
- Galvan Diaz, F.; Morales, R.N. HIV/AIDS in Mexico. AIDS Action 1990, 6–7. [Google Scholar] [PubMed]
- Horyniak, D.; Wagner, K.D.; Armenta, R.F.; Cuevas-Mota, J.; Hendrickson, E.; Garfein, R.S. Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California. Int. J. Drug Policy 2017, 47, 9–17. [Google Scholar] [CrossRef]
- Acero Fernandez, D.; Ferri Iglesias, M.J.; Buxo Pujolras, M.; Lopez Nunez, C.; Serra Matamala, I.; Queralt Moles, X.; Aldeguer Mante, X. Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years. Gastroenterol. Hepatol. 2018, 41, 2–11. [Google Scholar] [CrossRef]
- Cantaloube, J.F.; Gallian, P.; Attoui, H.; Biagini, P.; De Micco, P.; de Lamballerie, X. Genotype distribution and molecular epidemiology of hepatitis C virus in blood donors from southeast France. J. Clin. Microbiol. 2005, 43, 3624–3629. [Google Scholar] [CrossRef]
- Library of Congress. Research Guides: Bracero Program; Library of Congress: Washington, DC, USA, 1942; p. 1. Available online: https://guides.loc.gov/latinx-civil-rights/bracero-program#s-lib-ctab-24941684-2 (accessed on 17 June 2024).
- The Wilson Center. Mexican Braceros and US Farm Workers; The Wilson Center: Washington, DC, USA, 2020; p. 1. Available online: https://www.wilsoncenter.org/article/mexican-braceros-and-us-farm-workers (accessed on 17 June 2024).
- US Citizenship and Immigration Services. Naturalization through Military Service, Form N-426; US Citizenship and Immigration Services: Washington, DC, USA, 2023; p. 1. Available online: https://www.uscis.gov/military/naturalization-through-military-service (accessed on 17 June 2024).
- Library of Congress. Racial, Ethnic, and Religious Minorities in the Vietnam War: A Resource Guide2022; Library of Congress: Washington, DC, USA, 2022; p. 1. Available online: https://guides.loc.gov/racial-ethnic-and-religious-minorities-in-the-vietnam-war#:~:text=The%20U.S.%20Army%20web%20site,of%20the%20general%20U.S.%20population (accessed on 17 June 2024).
- Robins, L.N.; Davis, D.H.; Goodwin, D.W. Drug use by U.S. Army enlisted men in Vietnam: A follow-up on their return home. Am. J. Epidemiol. 1974, 99, 235–249. [Google Scholar] [CrossRef] [PubMed]
- Stur, H.M. The Myth of the Addicted Army: Vietnam and the Modern War on Drugs (Review). J. Soc. Hist. 2012, 45, 868–870. Available online: https://muse.jhu.edu/pub/8/article/468507 (accessed on 18 June 2024).
- Ponce de León, S.; Macías, A.E.; Cruz, A.; Calva, J.; Carlos Tinoco, J.; Ruiz, C.; Ojeda, F.; Bobadilla, M.; Lilia Rolón, A.; Villalobos, I.; et al. Los primeros cinco años de la epidemia de SIDA en México. Salud Publica Mex 1988, 30, 544–554. [Google Scholar] [PubMed]
- Gobierno de México. Epidemiología Registro Nacional de Casos de VIH y sida 2024; Gobierno de México: Mexico City, Mexico, 2024; p. 1. Available online: https://www.gob.mx/censida/documentos/epidemiologia-registro-nacional-de-casos-de-sida (accessed on 18 June 2024).
- National Institutes of Health. HIV and Hepatitis C; National Institutes of Health: Bethesda, MD, USA, 2021; p. 1. Available online: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-hepatitis-c (accessed on 18 June 2024).
- Gobierno de México. Dirección General de Epidemiología Anuario de Morbilidad 1984–2022; Gobierno de México: Mexico City, Mexico, 2024; p. 1. Available online: https://epidemiologia.salud.gob.mx/anuario/html/ (accessed on 18 June 2024).
- United States General Accounting Office. Drug Control. DEA’s Strategies and Operations in the 1990s; United States General Accounting Office: Washington, DC, USA, 1990; p. 48. Available online: https://www.gao.gov/assets/ggd-99-108.pdf (accessed on 18 June 2024).
- Congressional Research Service. Mexico: Organized Crime and Drug Trafficking Organizations; Congressional Research Service: Washington, DC, USA, 2022; p. 11. Available online: https://sgp.fas.org/crs/row/R41576.pdf (accessed on 18 June 2024).
- Brouwer, K.C.; Case, P.; Ramos, R.; Magis-Rodríguez, C.; Bucardo, J.; Patterson, T.L.; Strathdee, S.A. Trends in production, trafficking, and consumption of methamphetamine and cocaine in Mexico. Subst. Use Misuse 2006, 41, 707–727. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Bucardo, J.; Brouwer, K.C.; Magis-Rodríguez, C.; Ramos, R.; Fraga, M.; Perez, S.G.; Patterson, T.L.; Strathdee, S.A. Historical trends in the production and consumption of illicit drugs in Mexico: Implications for the prevention of blood borne infections. Drug. Alcohol. Depend 2005, 79, 281–293. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- United Nations. Drug Trafficking; United Nations: New York, NY, USA, 2010; p. 2. Available online: https://www.unodc.org/unodc/en/drug-trafficking/index.html (accessed on 18 June 2024).
Variable | Category | HIV/HCV (N = 66) | HCV (N = 194) | p-Value |
---|---|---|---|---|
Gender | Female | 9 (13.6%) | 119 (61.3%) | |
Male | 57 (86.4%) | 75 (38.7%) | <0.001 1 | |
Age (year) | Median (Q1, Q3) | 40.5 (35.2, 46.0) | 53.0 (44.0, 59.0) | <0.001 2 |
Injection drug use | Absent | 38 (57.6%) | 158 (85.9%) | |
Present | 28 (42.4%) | 26 (14.1%) | <0.001 1 | |
Blood transfusion | Absent | 37 (56.1%) | 61 (33.3%) | |
Present | 29 (43.9%) | 122 (66.7%) | 0.001 1 | |
Surgery | Absent | 28 (42.4%) | 33 (17.9%) | |
Present | 38 (57.6%) | 151 (82.1%) | <0.001 1 | |
Tattooing | Absent | 27 (40.9%) | 134 (72.8%) | |
Present | 39 (59.1%) | 50 (27.2%) | <0.001 1 | |
Piercing | Absent | 46 (69.7%) | 180 (97.8%) | |
Present | 20 (30.3%) | 4 (2.2%) | <0.001 1 | |
Dental procedures | Absent | 43 (65.2%) | 134 (72.8%) | |
Present | 23 (34.8%) | 50 (27.2%) | 0.239 1 | |
Hemodialysis | Absent | 65 (98.5%) | 180 (97.8%) | |
Present | 1 (1.5%) | 4 (2.2%) | 0.743 1 | |
Acupuncture | Absent | 61 (92.4%) | 155 (84.2%) | |
Present | 5 (7.6%) | 29 (15.8%) | 0.096 1 | |
Imprisonment | Absent | 39 (59.1%) | NA | |
Present | 27 (40.9%) | NA | ||
Health worker | Absent | 65 (98.5%) | 179 (97.3%) | |
Present | 1 (1.5%) | 5 (2.7%) | 0.584 1 | |
Sexual worker | Absent | 57 (86.4%) | NA | |
Present | 9 (13.6%) | NA | ||
HCV viral load (IU/mL) | Median (Q1, Q3) | 4,480,000.0 (941,500.0, 15,625,000.0) | 2,925,000.0 (680,000.0, 10,300,000.0) | 0.331 2 |
HCV subtyping method | LiPA | 31 (47.0%) | 79 (40.7%) | |
Sanger sequencing | 35 (53.0%) | 115 (59.3%) | 0.375 1 | |
HCV subtype | 1a | 45 (68.2%) | 107 (55.2%) | 0.064 1 |
1b | 7 (10.6%) | 43 (22.2%) | 0.040 1 | |
2a | 1 (1.5%) | 1 (0.5%) | 0.422 1 | |
2b | 2 (3.0%) | 12 (6.2%) | 0.327 1 | |
3a | 10 (15.2%) | 24 (12.4%) | 0.563 1 | |
4a | 1 (1.5%) | 0 (0.0%) | 0.086 1 | |
2a/2c | 0 (0.0%) | 7 (3.6%) | 0.118 1 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Laguna-Meraz, S.; Jose-Abrego, A.; Roman, S.; Leal-Mercado, L.; Panduro, A. Risk Factors Associated with Hepatitis C Subtypes and the Evolutionary History of Subtype 1a in Mexico. Viruses 2024, 16, 1259. https://doi.org/10.3390/v16081259
Laguna-Meraz S, Jose-Abrego A, Roman S, Leal-Mercado L, Panduro A. Risk Factors Associated with Hepatitis C Subtypes and the Evolutionary History of Subtype 1a in Mexico. Viruses. 2024; 16(8):1259. https://doi.org/10.3390/v16081259
Chicago/Turabian StyleLaguna-Meraz, Saul, Alexis Jose-Abrego, Sonia Roman, Leonardo Leal-Mercado, and Arturo Panduro. 2024. "Risk Factors Associated with Hepatitis C Subtypes and the Evolutionary History of Subtype 1a in Mexico" Viruses 16, no. 8: 1259. https://doi.org/10.3390/v16081259
APA StyleLaguna-Meraz, S., Jose-Abrego, A., Roman, S., Leal-Mercado, L., & Panduro, A. (2024). Risk Factors Associated with Hepatitis C Subtypes and the Evolutionary History of Subtype 1a in Mexico. Viruses, 16(8), 1259. https://doi.org/10.3390/v16081259